NN
NNLX.US Nanologix Inc
- Market cap
- USD 15.9K
- P/E
- -
- P/B
- -
- ROE
- -211.7%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2013.
Is NNLX.US undervalued?
Graham numberThe Graham number of Nanologix Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Nanologix Inc fundamental analysis
No fundamental analysis for Nanologix Inc yet.
Nanologix Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Nanologix Inc
NanoLogix, Inc., a biotechnology company, provides diagnostics of viable microorganisms and viruses. It offers rapid viral assay test, which is a method for detection and quantification of a virus; and N-assay diagnostics that furnish the ability to detect and identify bacteria and other microorganisms for pharmaceutical, industrial, veterinary, and environmental testing, as well as microbiology, soil microbiology and bioremediation, microbial physiology, pharmacology, pharm…
Full company profileNanologix Inc financial statements
Nanologix Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 |
|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||
| Revenue | - | - | 20.6K | 25.0K | 21.4K | 640.00 | 892.00 | 88.3K | 35.6K |
| Gross Profit | -34.2K | -40.9K | - | 25.0K | 17.4K | -20.1K | -927K | -858K | -710K |
| Operating Income | -1.58M | -2.29M | -1.31M | -1.16M | -1.07M | -2.65M | -1.86M | -1.76M | -1.30M |
| EBITDA | -1.56M | -2.29M | -1.26M | -1.22M | -1.11M | -2.53M | -1.71M | -1.62M | -1.18M |
| Net Income | -1.60M | -2.33M | -1.31M | -1.27M | -1.16M | -2.66M | -1.86M | -1.75M | -1.29M |
| EPS | -0.04 | -0.04 | -0.02 | -0.01 | -0.01 | -0.02 | -0.02 | -0.01 | -0.01 |
| Balance Sheet | |||||||||
| Total Assets | 356K | 806K | 1.07M | 704K | 695K | 1.16M | 921K | 890K | 727K |
| Total Liabilities | 97.4K | 134K | 108K | 344K | 290K | 32.4K | 9.40K | 2.07K | 116K |
| Shareholders' Equity | 258K | 672K | 967K | 360K | 405K | 1.13M | 912K | 888K | 611K |
| Cash & Short-term Investments | 341.00 | 58.2K | 175K | 16.3K | 88.6K | 211K | 115K | 63.6K | 3.34K |
| Total Debt | 1.57K | - | - | 29.8K | 37.0K | - | - | - | 100K |
| Cash Flow | |||||||||
| Operating Cash Flow | -466K | -787K | -764K | -306K | -237K | -1.01M | -1.10M | -1.11M | -697K |
| Capital Expenditure | 4.00 | 1.00 | 29.7K | 4.00 | 214K | 446K | 24.7K | 41.3K | 4.00 |
| Free Cash Flow | -466K | -787K | -794K | -306K | -451K | -1.46M | -1.12M | -1.15M | -697K |
| Ratios | |||||||||
| ROE | -618.1% | -347.2% | -135.8% | -353.2% | -286.3% | -236.1% | -204.1% | -196.7% | -211.7% |
| ROA | -448.9% | -289.3% | -122.2% | -180.7% | -166.9% | -229.5% | -202.0% | -196.2% | -177.9% |
| Net Profit Margin | - | - | -6,370.6% | -5,088.7% | -5,430.8% | -414,966.3% | -208,618.7% | -1,977.3% | -3,631.2% |
| Debt to Equity | 0.01x | - | - | 0.08x | 0.09x | - | - | - | 0.16x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Nanologix Inc dividends
Nanologix Inc has not paid dividends in the last 9 fiscal years.
Who owns Nanologix Inc
Ownership data of Nanologix Inc is not available yet.
Nanologix Inc company profile
- Company name
- Nanologix Inc
- Ticker
- NNLX.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Biotechnology
- Fiscal year end
- December
- Address
- 843 North Main Street, Hubbard, OH, United States, 44425
- Phone
- 330-534-0800
- Website
- nanologix.com
About Nanologix Inc
NanoLogix, Inc., a biotechnology company, provides diagnostics of viable microorganisms and viruses. It offers rapid viral assay test, which is a method for detection and quantification of a virus; and N-assay diagnostics that furnish the ability to detect and identify bacteria and other microorganisms for pharmaceutical, industrial, veterinary, and environmental testing, as well as microbiology, soil microbiology and bioremediation, microbial physiology, pharmacology, pharmaco-kinetics, and antibiotic sensitivity sectors. The company sells its products to established medical and scientific entities, including laboratories, medical institutions, universities, businesses, and research establishments. NanoLogix, Inc. is based in Hubbard, Ohio.
Nanologix Inc management
2- Mr. Bret T. BarnhizerChairman, CEO & President · born 1951
- Ms. Carol J. SurrenaCorporate Secretary